Abstract
Background: Atherosclerotic peripheral artery disease (PAD) affects a growing number of patients in aging populations. Peripheral artery disease (PAD) accounts for a large proportion of cardiovascular disease (CVD) prevalence in most world regions. Objective: This study aims to evaluate and compare the patency, clinical outcome, and limb salvage rates between the simple percutaneous Transluminal angioplasty and the drug-coated balloons in chronic total occlusion of the femoropopliteal arterial segment on the short-term course. Patients and Method: A prospective randomized controlled comparative study was conducted in the vascular surgery department; Aswan University Hospital during the period from March 2018 to March 2020. In total, 30 patients with a well-established diagnosis of superficial femoral artery (SFA) and/or proximal popliteal lesions with symptoms of PAD. Results: The primary patency at 12-month following treatment with DCB was significantly better 100. %, 80.0%, 60.0% at 1, 6, 12 months compared with POBA 86.7 %, 66.7%, 46.7% at 1, 6, 12 months. The rate of clinically- driven TLR was the same in both groups (26.6%). The use of DCB was safe and did not increase the major adverse clinical events (death, myocardial infarction, and minor or major amputation) when compared with those seen with the use of the uncoated balloons). Conclusion: Use of DCBs is associated with improved vessel patency when compared to POBA in patients with FPD. There was no difference in clinically driven TLR between DCB and POBA in our study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.